Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-3512676 + paclitaxel + carboplatin
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Small Molecules, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
PF-3512676 + paclitaxel + carboplatin is a combination therapy investigated for the treatment of advanced non-small cell lung cancer (NSCLC). PF-3512676 (formerly known as CPG 7909) is a synthetic oligodeoxynucleotide that acts as an agonist of Toll-like receptor 9 (TLR9), stimulating innate immune responses and potentially enhancing antitumor immunity. Paclitaxel is a microtubule-stabilizing agent that inhibits cell division, while carboplatin is a platinum-based chemotherapeutic that causes DNA crosslinking and apoptosis in rapidly dividing cells. The rationale for combining these agents was to augment the efficacy of standard chemotherapy with immunostimulatory effects from PF-3512676. However, phase III clinical trials showed no improvement in overall survival or progression-free survival with the addition of PF-3512676 to paclitaxel/carboplatin compared to chemotherapy alone, and increased toxicity was observed[2][4][5].
- Other names
- CPG 7909 + paclitaxel + carboplatin
02
Targets
TLR9 (Toll-like receptor 9)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on PF-3512676 + paclitaxel + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-3512676 + paclitaxel + carboplatin.